Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Xiangnan Guan(Unknown), Namrata S. Patil(Gene Therapy Laboratory), Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), John Silva, Barzin Y. Nabet(Gene Therapy Laboratory), Shyam Srivats, Katherine Nutsch, Pallavi Daggumati, Lisa McGinnis(Stanford Medicine), Alexis Dunkle(Duke University Hospital), Robert L. Hendricks(University of Pittsburgh), David S. Shames(Gene Therapy Laboratory), Melissa L. Johnson(Tennessee Oncology), Nandini Molden, Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Wendy Connolly, Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Byoung Chul Cho(Yonsei University), Ignacio Gil‐Bazo(Navarre Institute of Health Research), Ira Mellman(Unknown), Patrick Chang, Robert J. Johnston(Gene Therapy Laboratory), Stephanie Mittman, Ellen Duong(IIT@MIT), Chia-Jung Han, Enriqueta Felip(Institut Català d'Ornitologia), Ruozhen Hu, Raymond D. Meng, Eugene Y. Chiang(Gene Therapy Laboratory), Yoonha Choi, Karl L. Banta(Cancer Research Institute)
Cited by 121
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k